Skip to content

Neogen NEOG Accounts Receivable

Accounts Receivable at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$603.54M+14.4%
Zoetis logo
ZoetisZTS
$1.51B+10.7%
Revvity logo
RevvityRVTY
$691.38M+12.0%
Agilent Technologies logo
Agilent TechnologiesA
$1.5B+9.7%
NeoGenomics logo
NeoGenomicsNEO
$167.42M+10.7%
Merck & Co. logo
Merck & Co.MRK
$12.21B+13.2%

Other financials

Income statement

See full
Revenue$211.2M-4.4%
Gross profit$99.0M-10.2%
Operating income-$3.3M-161%
Net income-$17.0M-56.0%
EPS (diluted)-$0.08-60.0%

Balance sheet

See full
Cash & equivalents$159.9M+25.2%
Total debt$793.3M-11.2%
Total equity$2.1B-21.0%
Total assets$3.4B-16.8%

Cash flow

See full
Operating cash flow$22.7M+16.7%
CapEx$11.6M-64.7%
Free cash flow$11.1M+182%

Valuation

See full
Market cap$2B+93.1%
Enterprise value$2.63B+45.5%
P/S2.3×+1.1×

Profitability

See full
Gross margin45.2%-3.6pp
Operating margin-73.1%+77.7pp
Net margin-69.9%+30.8pp
FCF margin-14%

Returns & leverage

See full
Return on equity-25.6%+28.8pp
Debt / equity0.4×0.0×
Current ratio3.9×0.0×

Where this comes from

Reported directly by Neogen in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The official record: Neogen’s 10-Q, filed April 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Neogen's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Neogen's accounts receivable?
Neogen (NEOG) reported accounts receivable of $137.1M in Q4 2025.
How has Neogen's accounts receivable changed year-over-year?
Neogen's accounts receivable decreased by 14.3% year-over-year, from $160.07M to $137.1M.
What is the long-term trend for Neogen's accounts receivable?
Over 4 years (2021 to 2025), Neogen's accounts receivable has grown at a 13.7% compound annual growth rate (CAGR), from $91.82M to $153.4M.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.